David Stoffel, MD

AI
Radiology AI: Going beyond the algorithm
Over 30% of radiologists are already using AI in their clinical practices, but it's vital recognize that not all AI is created equal and it must have a true clinical, operational, and financial impact, writes Dr. David Stoffel.
June 3, 2024
2021 05 24 Solis Ai Visual
Page 1 of 1
Top Stories
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Interventional
Image-guided focal laser ablation effective for prostate cancer
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
Gioele Gatto/Pexels
CT
Spain's radiology society warns CT renewal still far short despite new procurement drive
Grad-CAM heatmaps showing the AI model's areas of attention overlaid on standard mammography views, as displayed to radiologists during the XAI-assisted reading sessions.
AI
AI can mislead radiologists -- and make the error more persuasive
Valencia became the center of Spanish radiology from 20–23 May as the city hosted SERAM 2026, one of the country's largest medical imaging meetings.
AI
SERAM 2026: AI-assisted triage in deep neck infections
Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.
Molecular Imaging
SNMMI: SPECT/CT tracer shows promise in interstitial lung disease
More in Home
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Spain's radiology society warns CT renewal still far short despite new procurement drive
By Claudia Tschabuschnig
SERAM's new equipment guide says Spain needs around 80 CT scanners a year. A new government purchasing framework covers 62 over two years, and the MRI and vascular equivalents are still missing.
June 3, 2026
Gioele Gatto/Pexels
AI can mislead radiologists -- and make the error more persuasive
By Claudia Tschabuschnig
A study from Milan puts hard numbers on how often radiologists follow a wrong AI recommendation and whether explainable AI can help.
June 2, 2026
Grad-CAM heatmaps showing the AI model's areas of attention overlaid on standard mammography views, as displayed to radiologists during the XAI-assisted reading sessions.
SERAM 2026: AI-assisted triage in deep neck infections
By Claudia Tschabuschnig
AI models trained on CT and laboratory data showed promise for predicting ICU admission, surgery and tracheostomy in patients with deep neck infections.
June 1, 2026
Valencia became the center of Spanish radiology from 20–23 May as the city hosted SERAM 2026, one of the country's largest medical imaging meetings.
SNMMI: SPECT/CT tracer shows promise in interstitial lung disease
By Will Morton
Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.
May 31, 2026
Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.
SNMMI: Machine-learning model predicts RPT dose
By Will Morton
Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.
May 30, 2026
Snmmi Thumb
Eye movement abnormalities flag brain health risk in ex-racing drivers
By Kate Madden Yee
A case series of 12 male retired professional motorsport drivers showed a high prevalence of mild neurological abnormalities.
May 29, 2026
Racecare Thumb
Video from RöKo 2026: Beckelmann on workforce reform, leadership, and radiology supply
By Claudia Tschabuschnig
Bettina Beckelmann discussed workforce reform, leadership, and radiology supply in a video interview at RöKo 2026.
May 29, 2026
Bettina Beckelmann, Managing Director of Beckelmann GmbH, a Dortmund-based family-owned radiology supplies company.
MMA embolization cuts recurrence risk in chronic subdural hematoma, trials show
By Claudia Tschabuschnig
Adding embolization to subdural hematoma surgery reduces recurrence rates, five randomized trials show.
May 28, 2026
71-year-old patient with headaches and unsteady gait. Coronal MRI before embolization demonstrating a chronic subdural hematoma (cSDH).
AI diagnostic aid helps novice MRI readers, but experts not so much
By Kate Madden Yee
The findings point to where AI decision support delivers the most clinical value.
May 26, 2026
Chat Gpt 3
RöKo 2026: Nikolaou on AI policy, data gaps, and a prostate cancer paradox
By Claudia Tschabuschnig
Many open questions remain around AI in radiology. One of Europe's leading voices tries to fill some of the blank spaces.
May 26, 2026
Prof. Dr. Konstantin Nikolaou, chairman of the Department of Diagnostic and Interventional Radiology at the University of Tübingen, and chair of the ESR's AI and Digital Technologies Committee is one of the most influential voices on AI governance in European radiology.
RöKo 2026: Lungenkrebs-Screening gestartet, die Arbeit beginnt jetzt
By Claudia Tschabuschnig
Sieben Jahre Vorarbeit, ein virtueller Starttermin, und ein Berg an administrativen Hürden, der noch erklommen werden muss.
May 25, 2026
Frühstadiumbefunde sind nicht immer eindeutig, multidisziplinäres Urteilsvermögen ist keine Formalität.' machte die Knötchenkonferenz am Ende der Highlight-Sitzung „Wir gegen Lungenkrebs', RöKo 2026, Leipzig, deutlich.
Page 1 of 84
Next Page